News

Kia ora,  Please follow this  link  to our website for the November 2025 Tender Notification. Ngā mihi, Stefanie Moir | Tender Analyst Te Pātaka Whaioranga | Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington | P: 0800 660 050 |  www.pharmac.govt.nz

From 1 March 2026 all HIV medicines will be able to be dispensed in three-month amounts, rather than monthly, making it easier for people to manage their treatment. In October, we consulted on three changes to the way New Zealanders access HIV medicines. Thank you to all those who provided feedback. In response to this feedback, we have delayed the proposed effective date from 1 December 2025 to 1 March 2026 to give everyone more time to adapt. We also decided not to remove Special...

Issue 334 - 27 November 2025 Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence of interest, with access to new content arranged by topic. You can forward this newsletter to others who may be interested in receiving it. They can register and subscribe here . You can also access other recent issues of the digest here. If you have any queries, please email us at  library@health.govt.nz Article Access For articles that aren't open access,...

Looking for a new challenge? We are seeking a passionate Registered Nurse to support the development of New Zealand nursing procedures.  Lippincott is offering a part-time, work-from-home, flexible, freelance clinical editor role.   Please see job description attached.

We are writing to inform you that Sanofi, the supplier of isoniazid 100mg with rifampicin 150mg ( Rifinah ) tab, has advised of a supply issue due to delays with manufacturing. The current stock has the expiry date 30 November 2025.    Key messages: An alternative brand Rifamazid  has been listed (funded) from 1 December 2025. This is an unapproved medicine and as such needs to be prescribed and dispensed in line with section 29 of the Medicines Act. It is estimated it will be available to...

We want your feedback on a proposal to fund nitisinone for people with rare inherited metabolic disorders, including tyrosinemia type 1 and alkaptonuria. Nitisinone is currently funded through Pharmac’s Named Patient Pharmaceutical Assessment (NPPA) pathway. Under this proposal, it would be listed on the Pharmaceutical Schedule, making it easier for clinicians to prescribe and helping ensure ongoing supply in New Zealand. More information about the proposal is available here The consultation...